INNATE PHARMA SA (IPH.PA)
FR0010331421 - Common Stock
IPH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 77 industry peers in the Biotechnology industry. IPH has a bad profitability rating. Also its financial health evaluation is rather negative. IPH is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IPH had negative earnings in the past year.
IPH had a negative operating cash flow in the past year.
IPH had negative earnings in each of the past 5 years.
IPH had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
IPH has a better Return On Assets (-4.11%) than 76.39% of its industry peers.
Looking at the Return On Equity, with a value of -14.59%, IPH is in the better half of the industry, outperforming 70.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.11% | ||
| ROE | -14.59% | ||
| ROIC | N/A |
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IPH has a Gross Margin of 94.50%. This is amongst the best in the industry. IPH outperforms 95.83% of its industry peers.
In the last couple of years the Gross Margin of IPH has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for IPH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
2. Health
2.1 Basic Checks
IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IPH has more shares outstanding
The number of shares outstanding for IPH has been increased compared to 5 years ago.
IPH has a better debt/assets ratio than last year.
2.2 Solvency
IPH has an Altman-Z score of -0.98. This is a bad value and indicates that IPH is not financially healthy and even has some risk of bankruptcy.
IPH has a Altman-Z score (-0.98) which is comparable to the rest of the industry.
IPH has a Debt/Equity ratio of 1.60. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IPH (1.60) is worse than 69.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.6 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.98 |
ROIC/WACCN/A
WACC6.11%
2.3 Liquidity
A Current Ratio of 3.73 indicates that IPH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.73, IPH is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
IPH has a Quick Ratio of 3.73. This indicates that IPH is financially healthy and has no problem in meeting its short term obligations.
IPH has a better Quick ratio (3.73) than 73.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.73 |
3. Growth
3.1 Past
IPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.13%, which is quite impressive.
IPH shows a small growth in Revenue. In the last year, the Revenue has grown by 4.68%.
The Revenue has been decreasing by -8.27% on average over the past years.
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q85.76%
Revenue 1Y (TTM)4.68%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Revenue growth Q2Q99.27%
3.2 Future
IPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.36% yearly.
The Revenue is expected to grow by 32.16% on average over the next years. This is a very strong growth
EPS Next Y28.86%
EPS Next 2Y42.31%
EPS Next 3Y45.36%
EPS Next 5YN/A
Revenue Next Year-18.68%
Revenue Next 2Y30.28%
Revenue Next 3Y42.23%
Revenue Next 5Y32.16%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IPH's earnings are expected to grow with 45.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.31%
EPS Next 3Y45.36%
5. Dividend
5.1 Amount
IPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INNATE PHARMA SA
EPA:IPH (4/25/2024, 7:00:00 PM)
2.18
-0.05 (-2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap176.24M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.11% | ||
| ROE | -14.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.6 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y28.86%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.68%
Revenue growth 3Y-2.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y